bioRxivMicrobiologyPreprint
A Monoclonal Antibody Panel to Track Antigenic Evolution of SARS-CoV-2 JN.1 Subvariants
Hsiang HongiD, Madeline Wu, Sue ChongiD, Jian YuiD, Ian A. MellisiD, Chien-Yu Huang, Qian WangiD, Yaoxing HuangiD, Yicheng GuoiD, David D. HoiD
Abstract
SARS-CoV-2 continues to evolve, generating successive variants with enhanced resistance to antibody-mediated neutralization. However, many existing monoclonal antibody (mAb) repertoires were derived from ancestral or early Omicron strains and have lost activity against contemporary variants, limiting their ability to resolve the antigenic effects of mutations arising in newly emerging lineages. Here, we generated a mAb panel by immunizing naive, unimprinted VelocImmune humanized mice with spike from the KP.3.1.1 variant, and isolated and characterized 11 neutralizing antibodies targeting diverse epitopes of recently evolved antigenic variants. We then integrated these antibodies with previously characterized mAbs to establish an expanded toolbox for profiling antigenic evolution among emerging variants. Application of this panel to currently emerging SARS-CoV-2 variants provided mechanistic insight into recent antigenic evolution, highlighting the potential role of altered receptor-binding domain conformation. Our data also revealed clear differences in antibody-evasion profiles between JN.1-derived lineages and BA.3.2 lineages. Together, our findings establish an updated mAb panel for monitoring antigenic evolution of JN.1 subvariants.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1
Fanchong Jian, Jing Wang, … Yunlong Cao·NaturePeer-reviewed·Nov 7, 2024
- Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants
Ian A. Mellis, Madeline Wu, … David D. Ho·Cell ReportsPeer-reviewed·Nov 24, 2025
- Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
A. Patel, S. Kumar, … E. A. Ortlund·bioRxiv·Oct 24, 2022
- Escape of SARS-CoV-2 variants KP1.1, LB.1 and KP3.3 from approved monoclonal antibodies
Delphine Planas, Isabelle Staropoli, … Olivier Schwartz·Pathogens and ImmunityPeer-reviewed·Sep 30, 2024
- Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2
Qian Wang, Yicheng Guo, … David D. Ho·Nature CommunicationsPeer-reviewed·Jul 4, 2025
- Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion
D. Planas, I. Staropoli, … O. Schwartz·bioRxiv·Nov 20, 2023